Nautilus Biotechnology Inc (NAUT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $295.50M
Last updated: Nov 17, 2026 at 11:06 AM ET
Nautilus Biotechnology Inc (NAUT) Stock Forecast
Analysts expect Nautilus Biotechnology (NAUT) to earn -$0.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $668500. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.49.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus is unchanged and revenue estimates rise 763.1%.
- Fiscal year ending Dec 31, 2026
- -$0.49
- EPS consensus, revenue $668500
- Fiscal year ending Dec 31, 2027
- -$0.49
- EPS consensus, revenue $5.77M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.49 | -$0.50 to -$0.44 | 4 | $668500 | $600000 to $700000 | 4 |
| Dec 31, 2027 | -$0.49 | -$0.55 to -$0.39 | 4 | $5.77M | $4.80M to $8.10M | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.15 to -$0.11 | 6 | $267750 | $196000 to $315000 | 6 |
| Mar 31, 2027 | -$0.12 | -$0.14 to -$0.09 | 3 | $387500 | $200000 to $500000 | 4 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.51.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.49 | -$0.51 | -$0.51 | -$0.51 | -$0.51 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.49 | -$0.52 | -$0.52 | -$0.52 | -$0.52 | N/A |
| Quarter ending Mar 31, 2027 | -$0.12 | -$0.12 | -$0.12 | -$0.09 | -$0.09 | N/A |
Frequently Asked Questions About NAUT
What is the NAUT stock forecast?
Consensus analyst estimates put Nautilus Biotechnology's EPS at -$0.49 for the fiscal year ending Dec 31, 2026, on revenue of $668500. The consensus rating from 4 analysts is Buy.
How do analysts rate NAUT stock?
Of 4 analysts covering Nautilus Biotechnology, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NAUT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.49, with estimates from -$0.50 to -$0.44 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.49, with estimates from -$0.55 to -$0.39 from 4 analysts.
What revenue do analysts expect from Nautilus Biotechnology next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $668500, with estimates from $600000 to $700000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.77M, with estimates from $4.80M to $8.10M.
How many analysts cover NAUT?
4 analysts rate Nautilus Biotechnology stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NAUT pages: Overview, Earnings, Forecast, Financials, Competitors